Pfizer and Moderna are producing fewer but more effective (and pricier) vaccines, while AstraZeneca is making a greater number of less effective (and cheaper) vaccines.
We've just gotten a whole bunch of good news – news we really needed – about finally getting the upper hand against COVID-19. Two vaccines, both more than 90% effective at protecting clinical trial participants against the disease, were announced just seven days apart. These numbers are well beyond expectations, but some critically important questions linger. Here they are. The answers will determine how successful the vaccines will be.
New York Governor Andrew Cuomo would rather allow more Americans to become infected with and die from coronavirus than to allow an imperfect vaccine distribution plan to proceed.
Pfizer's vaccine is based on RNA, which is a very unstable molecule that is prone to breaking down. Storing it at -94° F prevents this, but it creates the logistical difficulty of transporting the vaccine.
Americans take comfort knowing that competition works to keep prices in check, which keeps businesses on their toes while they deliver price-trimming benefits to consumers. However, when it comes to the market for medication that treats erectile dysfunction, that assumption simply and shockingly does not apply.
ACSH friend, Dr. Robert Popovian, the Senior Director of Healthcare, Science and Economic Advocacy and U.S. Government Relations at Pfizer, is arguably one of the world s premier experts in all aspects of the industry, from early stage discovery to development, as well as innovation, economics, and government policy.
Today we give a shout-out to ACSH friend Michael D. Shaw for his provocative piece that was posted on the HealthNewsDigest website. This topic is something we have written about regularly: What happens to pharmaceutical research when big companies merge and/or layoff scientists?
A new Pfizer-developed anti-cancer drug the first member of a new class of oncology drugs provided a longer progression-free period compared to the control group. Women with advanced
Pneumococcal disease kills almost 2 million people each year. Most of those deaths are individuals from poor countries and half are younger than five years of age. Prevnar 13 which protects against 13 strains of pneumonia